-transparent.png){kind=logo}
In this study we investigated the central effects of adinazolam, a triazolobenzodiazepine, by means of neurophysiological techniques (electroencephalogram, EEG, and quantified analysis of EEG, QEEG). The drug has been administered at the doses of 0.1-1-10 mg/kg i.v. The evaluation of the data obtained by QEEG has demonstrated that this substance acts on the central nervous system. Particularly we observed that the drug at the middle and high doses caused an increase of the "slow waves sleep" EEG pattern. This preclinical study has shown that adinazolam possesses a neuropharmacological profile similar to that of atypical antidepressive and/or anxiolytic drugs.
Related Publications
P Bo, and
R Murelli, and
D Soragna, and
D Ferrandi, and
F Savoldi
November 1983,
Neuropharmacology,
P Bo, and
R Murelli, and
D Soragna, and
D Ferrandi, and
F Savoldi
January 1986,
Psychopharmacology,
P Bo, and
R Murelli, and
D Soragna, and
D Ferrandi, and
F Savoldi
March 1984,
European journal of pharmacology,
P Bo, and
R Murelli, and
D Soragna, and
D Ferrandi, and
F Savoldi
September 1973,
Current therapeutic research, clinical and experimental,
P Bo, and
R Murelli, and
D Soragna, and
D Ferrandi, and
F Savoldi
August 1984,
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
P Bo, and
R Murelli, and
D Soragna, and
D Ferrandi, and
F Savoldi
March 1988,
Arzneimittel-Forschung,
P Bo, and
R Murelli, and
D Soragna, and
D Ferrandi, and
F Savoldi
March 1988,
Il Farmaco; edizione scientifica,
P Bo, and
R Murelli, and
D Soragna, and
D Ferrandi, and
F Savoldi
November 1971,
Electroencephalography and clinical neurophysiology,
P Bo, and
R Murelli, and
D Soragna, and
D Ferrandi, and
F Savoldi
December 1988,
Ceskoslovenska farmacie,
P Bo, and
R Murelli, and
D Soragna, and
D Ferrandi, and
F Savoldi
December 1969,
Hospital (Rio de Janeiro, Brazil),
